Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,606.49
(
-0.27%
)
US TECH 100
23,720.80
(
0.00%
)
Dow Jones
46,021.43
(
-0.44%
)
Brent Oil
104.33
(
-0.10%
)
Bitcoin
70,997.00
(
1.57%
)
News Focus
News Focus
Post# of 257262
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

acgood

Send PM Follow Ignore
Followers 17
Posts 1093
Boards Moderated 0
Alias Born 05/12/2007

acgood

Re: jq1234 post# 142643

Friday, 05/25/2012 9:53:18 PM

Friday, May 25, 2012 9:53:18 PM

Post# of 257262
Interesting that both ALNY and ISIS act confidently that the TTR composite surrogate endpoint employed for tafamidis will be acceptable for their respective pivotal trials. Maybe not so definite?

Opinions and comments may have been previously posted @BioDueDiligence, at www.biotechduediligence.com, or disseminated to Chimera Research Group subscribers.

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now